Searchable abstracts of presentations at key conferences in endocrinology

ea0049oc9.4 | Thyroid Disease 2 | ECE2017

Thyroid dysfunction during the use of PD-1/PD-L1 blockade predicts its therapeutic response in the patients with advanced non-small cell lung cancer

Kim Hye In , Kim Tae Hyuk , Jang Hye Won , Kim Young Nam , Kim Hosu , Park So Young , Kim Sun Wook , Chung Jae Hoon

Background: PD-1/PD-L1 blockade is one of the promising drugs in the treatment of advanced non-small cell lung cancer (NSCLC). and predicting drug effect is important due to unique pattern of response. Immune-related adverse event (IRAE) might be associated with favorable clinical outcome. Thyroiditis is the most common IRAE which can be easily detected with the measurement of thyroid hormone levels. However, the relationship between thyroid dysfunction during the use of PD-1/...

ea0049gp219 | Thyroid 3 | ECE2017

Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy in patients with differentiated thyroid cancer

In Kim Hye , Hyuk Kim Tae , Nam Kim Young , Kim Hosu , Young Park So , Jae Chung Yun , Hoon Chung Jae , Wook Kim Sun

Background: Delayed thyroid-stimulating hormone (TSH) recovery during treatment of GravesÂ’ disease is caused by long-term excessive thyroid hormone, which results in down-regulation of pituitary thyrotropic cells. However, it is unknown whether delayed TSH recovery exists after levothyroxine (LT4) dose adjustment in patients with differentiated thyroid cancer (DTC) who are taking a suppressive dose of LT4.Methods: We retrospectively reviewed 97 DTC ...